Saturday 17 October 2026 Export IBIO’s income statement to Excel — free account

iBio, Inc.

In the quarter to June 2026, revenue grew 100.0%, EPS grew 77.4% and free cash flow fell 35.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.77 0.01 −1.28%

Follow IBIO

Alert me

Market cap: $47.6M
P/E: 0.0×
Fwd P/E: −7.7×
Dividend yield: —
F-score: 4/9
Altman Z: 2.80
Beneish M: 33.49
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.10

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	3	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 46.51%

Capital & Financial Ratios $m

Market Cap 47.63

Revenue 0.68

Net Income (33.04)

Free Cash Flow (23.80)

Net Debt (88.04)

Current Ratio 7.85

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (7.74)

P/S ratio 118.71

P/B ratio 0.93

Past 5Y EPS Growth —

This Y EPS Growth (23.21%)

Next Y EPS Growth (49.64%)

Next Y revenue growth (75.00%)

Next 5Y EPS Growth (21.32%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 87.14%

10-year low 10-year high

P/B against its own 10 years 30.50%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	2026
Cash	7	15	9	88
Receivables	0	1	0	1
Inventory	—	—	—	—
Other	18	—	—	—
	26	16	10	92

	2023	2024	2025	2026
Payables	2	0	2	4
ST’ Debt	13	0	1	—
Other	2	0	1	1
	22	4	6	12

Compound Annual Growth %

	10y	5y	3y
Sales	(25.31%)	(42.83%)	(62.42%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	13.55%	(4.62%)	77.29%

Revenue $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	0	—	—	—	0
’25	—	0	—	0	0
’24	0	—	—	0	0
’22	0	0	2	0	2
’21	0	1	1	0	2
’20	0	0	0	1	2

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	(6)	(5)	(6)	(6)	(23)
’25	(4)	(4)	(3)	(5)	(15)
’24	(5)	(5)	(4)	(5)	(19)
’23	(14)	(8)	(4)	(5)	(30)
’22	(9)	(11)	(6)	(12)	(37)
’21	(7)	(8)	(7)	(7)	(30)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	(6)	(6)	(6)	(6)	(24)
’25	(4)	(4)	(3)	(5)	(15)
’24	(5)	(5)	(3)	(5)	(18)
’23	(16)	(11)	(2)	(5)	(34)
’22	(13)	(13)	(8)	(15)	(49)
’21	(8)	(9)	(8)	(10)	(35)

Fiscal quarters ending in the months shown.

EPS $

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	(0.11)	(0.09)	(0.07)	(0.07)	(0.32)
’25	(0.46)	(0.48)	(0.49)	(0.31)	(1.75)
’24	(4.80)	(4.42)	(0.85)	3.57	(6.50)
’23	(41.01)	(68.40)	(11.07)	14.33	(106.20)
’22	(20.00)	(25.00)	(30.00)	(39.08)	(115.60)
’21	(25.00)	(20.00)	(20.00)	0.00	(60.00)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	700.00	250.00	25.00	105.00	265.00	7.20	1.16	1.02	0.56	0.73	Analyst estimates 2027–2029 Powerpack
	High	2,800.00	1,750.00	700.00	3,725.00	1,415.00	330.00	52.00	4.98	6.89	3.13
People
People	Employees	8	8	55	51	75	116	23	16	20	23
	Revenue/emp, $m	0.05	0.06	0.04	0.03	0.03	0.02	0.00	0.01	0.02	0.00
Income, $m
Income, $m	Revenue	0	0	2	2	2	2	—	0	0	0
	Gross margin, %	100.00	100.00	100.00	57.08	38.34	100.00	0.00	100.00	100.00	100.00
	EBT	(16)	(16)	(18)	(16)	(23)	(30)	(29)	(15)	(18)	(33)
	EBT margin, %	(4,096.19)	(3,627.93)	(872.00)	(1,003.91)	(979.04)	(1,566.51)	0.00	(6,863.56)	(4,594.25)	(33,044.00)
	Net income	(16)	(16)	(18)	(16)	(23)	(50)	(65)	(25)	(18)	(33)
	Depreciation	2	2	2	2	3	4	2	1	1	1
Per share, $
Per share, $	Revenue	22.13	20.85	53.25	13.04	6.06	4.32	0.00	0.06	0.04	0.00
	Earnings	(800.00)	(664.53)	(464.43)	(305.00)	(60.00)	(115.60)	(106.20)	(6.50)	(1.75)	(0.32)
	Cash flow	(739.49)	(632.86)	(368.73)	(106.25)	(76.83)	(85.94)	(49.73)	(4.84)	(1.46)	(0.22)
	Capex	(89.49)	(50.66)	(26.12)	(9.19)	(13.19)	(26.67)	(5.13)	0.24	0.00	(0.01)
	Free cash flow	(828.99)	(683.52)	(394.85)	(115.44)	(90.02)	(112.61)	(54.86)	(4.61)	(1.46)	(0.23)
	Book value	500.84	758.87	64.83	450.69	277.45	145.57	25.13	5.57	1.42	0.82
	Shares, m	0	0	0	0	0	0	1	4	10	104
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	—	0.00	0.00	0.00
	P/S	88.10	20.87	6.57	85.11	124.60	27.63	—	3.80	12.77	269.79
	P/B	3.89	0.57	5.40	2.46	2.72	0.89	—	0.36	0.54	2.12
	EV/Sales	131.23	41.03	16.61	71.56	97.50	24.77	—	(2.94)	1.39	141.38
	EV/FCF	(3.50)	(1.25)	(2.24)	(8.00)	(6.56)	(1.03)	—	0.31	(0.05)	(3.94)
Cash, $m
Cash, $m	Operating cash flow	(13)	(13)	(14)	(13)	(30)	(37)	(30)	(19)	(15)	(23)
	Capex	(2)	(1)	(1)	(1)	(5)	(12)	(3)	1	0	(1)
	Free cash flow	(15)	(15)	(15)	(14)	(35)	(49)	(34)	(18)	(15)	(24)
Balance, $m
Balance, $m	Working capital	7	14	1	57	98	15	4	12	4	80
	Total debt	25	25	25	33	33	26	14	1	1	—
	Net debt	17	9	20	(22)	(64)	(8)	6	(14)	(8)	(88)
	Shareholders’ equity	9	16	2	57	109	63	15	21	15	86
Returns, %
Returns, %	ROA	(33.38)	(41.38)	(48.47)	(61.33)	(19.46)	(40.91)	(92.47)	(71.22)	(70.79)	(54.04)
	ROIC	(34.19)	(35.13)	(43.05)	(25.44)	(43.88)	(33.36)	(84.34)	(135.39)	(163.11)	0.00
	ROE	(88.73)	(130.51)	(191.75)	(129.55)	(28.41)	(58.58)	(164.86)	(135.71)	(101.52)	(65.70)

Negative figures in brackets.

All 10 years →

Fiscal years to Jun 2026 · latest quarter Sep 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MREO Mereo BioPharma Group plc - Sponsored ADR	$49.3M	— (loss-making)	— (loss-making)	—	n/m	+21.02% (above 0%: growing)	0.00%	0.00%	Compare
HYPD Hyperion DeFi, Inc.	$49.0M	— (loss-making)	3.6×	+2,333.33% (above 0%: growing)	n/m	+86.82% (above 0%: growing)	100.00%	8,668.63%	Compare
HOWL Werewolf Therapeutics, Inc.	$48.5M	— (loss-making)	— (loss-making)	+256.11% (above 0%: growing)	n/m	+146.46% (above 0%: growing)	100.00%	34.09%	Compare
ELTX Elicio Therapeutics, Inc.	$48.2M	— (loss-making)	— (loss-making)	−55.27% (below 0%: shrinking)	n/m	+8.77% (above 0%: growing)	0.00%	0.00%	Compare
ACET Adicet Bio, Inc.	$48.1M	— (loss-making)	— (loss-making)	+727.73% (above 0%: growing)	n/m	+24.94% (above 0%: growing)	0.00%	0.00%	Compare
KLRS Kalaris Therapeutics Inc.	$47.8M	— (loss-making)	—	—	n/m	+11.91% (above 0%: growing)	0.00%	0.00%	Compare
IBIO iBio, Inc.	$47.6M	— (loss-making)	— (loss-making)	+100.00% (above 0%: growing)	n/m	−35.33% (below 0%: shrinking)	100.00%	0.00%
CLNN Clene Inc.	$47.0M	— (loss-making)	— (loss-making)	+233.33% (above 0%: growing)	n/m	+45.43% (above 0%: growing)	60.00%	(5,941.11%)	Compare
TVGN Tevogen Inc.	$46.1M	— (loss-making)	—	—	n/m	+5.78% (above 0%: growing)	—	0.00%	Compare
Median of peers	$48.2M	—	—	+256.11%	—	+22.98%	0.00%	0.00%

All 614 Biotechnology stocks →

iBio, Inc. (IBIO) key facts

iBio, Inc. (IBIO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, IBIO traded at $0.77, a market capitalization of $47.6 million.
Return on equity was −65.7% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 2.80 (grey zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.